Accounts Receivable, after Allowance for Credit Loss, Current of Seres Therapeutics, Inc. from 31 Mar 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Seres Therapeutics, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 31 Mar 2019 to 31 Dec 2025.
  • Seres Therapeutics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 31 Dec 2025 was $157,000.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

Seres Therapeutics, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $157,000 +$157,000 31 Dec 2025 10-K 12 Mar 2026 2025 FY
Q3 2025 $351,000 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q4 2024 $0 31 Dec 2024 10-K 12 Mar 2026 2025 FY
Q3 2021 $1,250,000 -$2,143,000 -63% 30 Sep 2021 10-Q 10 Nov 2021 2021 Q3
Q2 2021 $1,251,000 -$1,678,000 -57% 30 Jun 2021 10-Q 03 Aug 2021 2021 Q2
Q1 2021 $2,604,000 +$520,000 +25% 31 Mar 2021 10-Q 04 May 2021 2021 Q1
Q4 2020 $9,387,000 +$7,602,000 +426% 31 Dec 2020 10-K 01 Mar 2022 2021 FY
Q3 2020 $3,393,000 +$1,676,000 +98% 30 Sep 2020 10-Q 09 Nov 2020 2020 Q3
Q2 2020 $2,929,000 +$1,325,000 +83% 30 Jun 2020 10-Q 28 Jul 2020 2020 Q2
Q1 2020 $2,084,000 -$4,583,000 -69% 31 Mar 2020 10-Q 07 May 2020 2020 Q1
Q4 2019 $1,785,000 31 Dec 2019 10-K 02 Mar 2021 2020 FY
Q3 2019 $1,717,000 30 Sep 2019 10-Q 05 Nov 2019 2019 Q3
Q2 2019 $1,604,000 30 Jun 2019 10-Q 06 Aug 2019 2019 Q2
Q1 2019 $6,667,000 31 Mar 2019 10-Q 02 May 2019 2019 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.